Incannex Healthcare Inc. (IXHL): Nasdaq/NYSE listing notice — Incannex receives Nasdaq bid price deficiency notice; cure period until Oct 20, 2025

Incannex Healthcare Inc.

Closing bid price of IXHL common stock below $1.00 for 30 consecutive trading days.
Nasdaq granted 180-day compliance period ending October 20, 2025.
If not compliant, Company may transfer to Nasdaq Capital Market for additional 180-day cure.
Lead asset IHL-42X (obstructive sleep apnea) Phase 2 top-line data expected before end of H1 2025.
Company evaluating options including reverse stock split to regain compliance.

item 3.01 item 8.01 item 3.02

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Incannex Healthcare Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5810(c)(3)(A)

Exact text from the filing

to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). This Notice is only a notification of a deficiency and has no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Global Market under the symbol “IXHL.” Pursuant to Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided an initial period of 180 calendar days, or until October 20, 2025 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. To regain compliance, the closing bid price of the Company’s Common Stock must m

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Incannex Healthcare Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-035636

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.